he restoration of coronary blood flow within 12 h of the onset of symptoms is essential for the treatment of patients with acute myocardial infarction (AMI) because successful coronary reperfusion can salvage at-risk myocardium and reduce mortality. 1,2 There are, however, some potential negative effects associated with rapid coronary reperfusion, such as myocardial stunning, arrhythmia, microvascular dysfunction, and myocardial cell death. 3, 4 Although it is yet to be confirmed clinically, the suppression of reperfusion injury would seem to be an attractive adjunctive treatment in the setting of AMI.
vention (LIMIT-2) trial was the first large-scale randomized clinical trial to show a significant reduction, compared with controls, for total mortality in patients treated with intravenous magnesium. 9 On the other hand, the recently published Magnesium in Coronaries (MAGIC) Trial in which the timing protocol for magnesium administration was almost identical to that in LIMIT-2, concluded that magnesium did not show a mortality benefit in patients with ST-elevation myocardial infarction. 10 Experimental studies indicate that reperfusion must be complete at or before the administration of magnesium in order to show the full cardioprotective effect. 4, 7, 8 The present study therefore comprises only patients undergoing primary percutaneous coronary intervention (PCI). This point makes the study quite different from the earlier randomized trials; it has been specifically designed to evaluate our hypothesis that the treatment of magnesium sulfate might show beneficial effects on pre-discharge left ventricular (LV) function and coronary microvascular function in patients with AMI.
Methods

Study Population
Between January 1999 and June 2002, 271 patients admitted to Nagasaki Citizens Hospital with a first AMI were initially eligible for inclusion in the study. Diagnosis of AMI was based on typical chest pain lasting >30 min, ST-segment elevation >1 mm in at least 2 contiguous limb leads, or ST-segment elevation >2 mm in at least 2 contiguous pre-cordial leads and an increase in serum creatine kinase (CK) to twice the normal upper value. Inclusion criteria for the study were as follows: (1) infarct-related artery (IRA) location in either the left anterior descending (LAD) or right coronary artery (RCA); (2) catheterization achieved <12 h after the onset of symptoms; (3) procedural success of primary PCI, defined as residual stenosis <30%.
A total of 91 patients were excluded from the study on the basis of delayed admission (n=42), IRA location in the left circumflex artery (n=43), IRA location in the left main trunk (n=3), or failed intervention (n=3). The remaining 180 subjects were randomly assigned to one of 2 groups: a magnesium group and a control group. All patients gave written informed consent prior to catheterization, and the study was approved by our institution's ethical committees.
Treatment Protocol
Prior to PCI, patients in the magnesium group received a bolus injection of 8 mmol of magnesium sulfate, which was followed by an infusion of 24 mmol over 24 h. The control group received an equivalent amount of normal saline. Oral aspirin (200 mg/day) and a bolus injection of heparin (10,000 U) were routinely given before PCI in both groups.
Primary PCI was performed according to conventional methods in all patients within 60 min of admission. In the event of inadequate lesion dilatation or a flow-limiting dissection, coronary stents were available for implantation. Collateral flow grade was assessed using the Rentrop classification. 11 Angiographic no-reflow was defined as flow less than TIMI grade 3 after PCI despite the absence of residual stenosis >50%, a dissection or distal thrombo-embolization. 12 Immediately after reperfusion, an infusion of 4 mg/h nicorandil was started for patients in both groups and continued for 3 days. Angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists were given to all patients not exhibiting hypotension, defined as <90 mmHg.
LV Function
Right anterior oblique views of the left ventriculograms were taken 21-28 days after intervention and analyzed by a single physician (TK) unaware of each patient's specific treatment group. The area -length method was used to calculate the LV ejection fraction (LVEF) and the enddiastolic volume index (EDVI). Regional wall motion (RWM) in the territory of the LAD or RCA was analyzed using the centerline method and expressed as standard deviations (SD) per chord. According to a previous study, the territories of the LAD and RCA extend from chords 10 to 66 and 51 to 80, respectively. 13 
Coronary Microvascular Function
Pre-discharge coronary flow velocity reserve (CFVR) was measured as an index of coronary microvascular function; it is generally accepted that CFVR may be taken as an index for coronary microvascular function in the absence of epicardial coronary stenosis >40% in diameter. 14, 15 To obtain CFVR, a 12 MHz Doppler guidewire (JoMetrics FloWire, JoMed, Rancho Cordova, CA, USA) connected to the FloMap velocimeter was advanced distal to the site of the lesion that had been dilated on admission. Average peak flow velocity (APV) was measured at baseline and at maximal hyperemia, induced by administration of intracoronary papaverine (8 mg to the RCA, 10 mg to the LCA). CFVR was defined as the ratio of maximal hyperemic APV to APV at baseline.
Statistical Analysis
Continuous variables are expressed as mean value ± SD and were compared using unpaired Student's t test. Dichotomous variables are expressed as counts and were compared using the chi-square test or Fisher's exact test. Statistical significance was defined as p<0.05.
Results
Patient characteristics are presented in Table 1 . There were more male patients in the magnesium group (n=89) than in the control group (n=91), but the difference did not reach statistical significance. There were no significant differences in terms of age, time to admission after onset, IRA-distribution and hemodynamic findings on admission in the 2 groups. Incidence of multivessel disease, and the availability of good collateral flow, defined as ≥Rentrop grade 2, were comparable in the 2 groups. The fact that there were no significant differences in terms of the coronary angiographic findings suggests that the degree of myocardium-at-risk was similar in both groups. There were also similar rates of stent use in the target lesions in the 2 sets of patients. Three patients in each group underwent adjunctive post-intervention thrombolysis because of residual thrombus.
Clinical Outcomes
Mortality and in-hospital complication rates are shown in Table 2 . One patient in the magnesium group and 3 in the control group died during admission: cause of death was cardiogenic shock in 3 cases and cerebral infarction in 1. Sixteen patients had angiographic no-reflow immediately after PCI and the incidence of this complication was significantly higher in the control group than in the magnesium group. Injection of intracoronary papaverine or verapamil was used in these patients to treat the no-reflow. Perfusion status improved to TIMI 3 flow in 11 of 16 patients, with the remaining 5 patients showing persistent no-reflow (TIMI 2 flow) despite treatment. The magnesium group showed a tendency to lower incidence of left-sided heart failure (Killip class II or III), occurring within 7 days of admission, but this did not reach statistical significance. There was similar incidence of cardiogenic shock, reinfarction, and ventricular fibrillation in the 2 groups. All 4 patients who suffered re-infarction were successfully reperfused by repeat coronary intervention. The angiographic patency rates in the IRA at the time of pre-discharge catheterization were 100% in the 2 groups.
LV Function
A comparison of LV function in the 2 groups is shown in Table 3 . Eleven patients did not undergo left ventriculography because of renal failure defined as serum creatinine level >2.5 mg/dl (n=5) and high LV end-diastolic pressure >25 mmHg (n=6). Because catheter-induced frequent ventricular premature contractions resulted in poor quality left ventriculograms in 6 patients, they were excluded from the analysis. Consequently, a total of 159 left ventriculograms were measured in 80 patients of the magnesium group and 79 patients of the control group. Both LVEF and RWM were significantly superior in the magnesium group than in the control group. Magnesium treatment subjects showed significantly decreased LV cavity size compared with their control counterparts.
The effects of magnesium on LV function seemed to differ with infarct location. In patients with an anterior myocardial infarction (MI), all 3 parameters, LVEF, RWM, and LVEDVI, were significantly superior in the magnesium group than in the control group (Table 4) , though there were no significant differences in these parameters between groups in patients with an inferior MI ( Table 5) . Magnesium sulfate was also effective in AMI complicated by acute left-sided heart failure or cardiogenic shock. Twenty-five patients with these complications in the magnesium group showed significantly better LV systolic performance and had a smaller LV end-diastolic volume than the 35 similar patients in the control group (LVEF: 61±12% vs 52±13%, p=0.016; RWM: -1.21±1.37 SD/chord vs -2.02±1.07 SD/chord, p=0.030; LVEDVI: 66±21 ml/m 2 vs 88±30 ml/m 2 , p=0.014).
Coronary Microvascular Function
Baseline APV was significantly lower in the magnesium group than in the control group (15.7±5.6 cm/s vs 19.6± 8.4 cm/s, p=0.021). Hyperemic APV was similar in the 2 groups (43.8±14.4 cm/s vs 43.3±16.2 cm/s, p=0.883). The rate -pressure product at baseline and at hyperemia was not different between the 2 groups. CFVR was significantly higher in the magnesium group than in the control group (2.95±0.76 vs 2.50±0.99, p=0.023) (Fig 1) .
Discussion
Models of ischemia -reperfusion have shown several underlying mechanisms for the cardioprotection conferred by magnesium sulfate. Christensen et al have shown that intravenous magnesium sulfate prior to reperfusion reduces infarct size in canine models by as much as 60% or more, 7 although use of magnesium after reperfusion does not seem to show this infarct-reducing effect. Herzog et al, who in their study used intracoronary magnesium sulfate at 2 different stages during and late in reperfusion, have emphasized that the timing of treatment profoundly affects the size of the infarct; a >50% reduction in infarct-size can be achieved only by the early use of magnesium during reperfusion. 8 Because transient calcium overload and the production of free radicals, both of which are key contributors to reperfusion injury, can both be inhibited by magnesium, suppression of reperfusion injury is one possible mechanism for the reduction in the size of the infarct. The consistent implication of the accumulated experimental studies is that magnesium sulfate should be given before or at the onset of reperfusion in order to maximize cardioprotection.
The administration of magnesium sulfate is not regarded as a standard treatment in the clinical setting of AMI, mainly because 3 major clinical trials, LIMIT-2, 9 ISIS-4 16 and the MAGIC trial, 10 drew conflicting conclusions in terms of mortality in the acute phase of MI. The LIMIT-2 Trial, comprising 2,316 patients with a suspected AMI, reported that all-cause mortality was significantly reduced, by 24%, in the magnesium group as compared with placebo. 9 Incidence of LV failure was also reduced in patients receiving magnesium sulfate. In contrast, the ISIS-4 Trial, with a patient population of 58,050 AMI subjects, failed to show any benefit on mortality and even suggested the slight possibility of harm. 16 The discrepancies between these 2 trials have been explained by the different timing of magnesium administration. In LIMIT-2, magnesium sulfate was given prior to thrombolysis, whereas in ISIS-4 magnesium was to be started after initiation of thrombolysis. If magnesium is going to suppress reperfusion injury, it is highly probable that delaying magnesium administration takes the effect outside the narrow therapeutic time window for magnesium to act. The recently published MAGIC trial, a randomized double-blind trial, examined the effect of magnesium on mortality in high-risk patients with STelevation myocardial infarction. This trial comprised 6,213 patients and entailed an administration schedule for magnesium sulfate similar to that of LIMIT-2, but unexpectedly, the MAGIC Trial concluded that early use of magnesium had no effect on 30-day mortality in reperfusion-eligible patients aged ≥65 years old, and reperfusion-ineligible patients of any age. However, it should be noted that the rate of use of reperfusion therapy in the MAGIC trial was low (25%) and that thrombolysis was used in a clear majority of patients (86%) who underwent reperfusion therapy. Therefore, the result of the MAGIC trial does not necessarily indicate the ineffectiveness of magnesium in patients who undergo primary coronary intervention, because coronary angioplasty can achieve higher patency rates than thrombolysis and reduces in-hospital complication rates. [17] [18] [19] In addition, rapid and complete reperfusion by angioplasty is quite different from gradual thrombolysis. Patients undergoing coronary intervention seem to be the most suitable model to test the cardioprotection of magnesium therapy that is apparent in the models of ischemia -reperfusion. The present study shows that magnesium administration results in significantly improved pre-discharge LV systolic function and smaller LV cavity size, which seems to confirm our hypothesis that magnesium can provide better functional outcomes in patients with AMI. One possible mechanism for this beneficial effect may be suppression of reperfusion injury. Although it is difficult to recognize and estimate the severity of reperfusion injury in the clinical setting, the low incidence of angiographic no-reflow and significantly higher CFVR in the magnesium group would seem to indicate that magnesium reduces coronary microvascular injury during reperfusion and preserves coronary microvascular function. It has already been established that patients' functional and clinical outcomes depend on real tissue perfusion grade after reperfusion. 20, 21 It follows that we may therefore speculate that the superior tissue perfusion obtained in patients treated with magnesium contributes to better LV function.
Another important finding is that the effect of magnesium varies according to infarct location. Patients with anterior MI appear to obtain more benefit from magnesium than those with an inferior MI. Meta-regression analysis of the results of the randomized clinical studies indicates that the estimated mortality benefit from magnesium will progressively develop as control group mortality increases. 22 The implication is that high-risk patients may receive greater benefit from magnesium: it is generally accepted that patients with an anterior MI have a larger infarct size and higher mortality rates than those with an inferior MI. If the deleterious effects of reperfusion increase with increasing infarct size, it is possible that patients with an anterior MI could benefit more from magnesium therapy than those with inferior MI.
There has only been one previous study that has evaluated the effect of magnesium on LV function in patients undergoing primary coronary intervention. Santoro et al reported that magnesium sulfate failed to show any beneficial effect on the infarct-zone wall motion score index assessed by echocardiogram. 23 This result at least is inconsistent with our own, though the 2 studies had a comparable number of patients and similar administration schedules, and also entailed similar overall doses of magnesium sulfate. However, patients with cardiogenic shock or advanced atrioventricular block were excluded from the other study, whereas we included patients with these complications. The differences in the study population may affect the results in the 2 studies. In terms of medical treatment, intravenous nicorandil, which is a hybrid of nitrate and an adenosine triphosphate-sensitive potassium channel opener, was used in all our study patients. Nicorandil dilates the coronary microvessels 24 in humans and may be expected to have a cardioprotective effect, because it has been shown that intravenous nicorandil in conjunction with primary PCI reduced in-hospital complications and improved long-term outcomes in AMI patients. 25, 26 One pilot study, in which the safety and efficacy of oral nicorandil was examined in patients with AMI and the timing of administration was not confined to the period before reperfusion therapy, suggested that nicorandil reduced the development of infarct progression in patients without a Qwave at the time of inclusion in the study. 27 In addition, one other report details the simultaneous use of intracoronary magnesium and nicorandil before reperfusion resulting in an increase in myocardial tissue blood flow, lower CK values and enhanced recovery of LV function in patients undergoing valve replacement. The synergic effect of magnesium and nicorandil may, at least in part, have contributed to the better LV function in our patients receiving magnesium treatment. 28 
Study Limitations
The study design was similar to that of the models of ischemia -reperfusion and our findings show the cardioprotective effects of magnesium as an adjunct to primary coronary intervention. However, caution should be used when interpreting the findings of this study because the study population was restricted to selected patients with a first anterior or inferior AMI and who underwent successful primary PCI. The benefit of magnesium in patients with reinfarction or treated by thrombolysis remains at best uncertain and is still controversial. Second, perfusion status after reperfusion was evaluated by visual assessment of TIMI perfusion grade. To ensure more accurate assessment of tissue perfusion grade, evaluation using myocardial contrast echocardiogram or Doppler coronary flow velocity pattern may be needed. Finally, the primary end-points for the study were the effects of magnesium on LV function and coronary microvascular function. To examine the full impact of this treatment on patient prognosis, a larger patient population may be needed.
Conclusions
Our findings suggest that magnesium sulfate given before primary coronary intervention results in beneficial effects on pre-discharge LV function and microvascular function in first-time AMI patients.
